LAKE OSWEGO, Ore.--(BUSINESS WIRE)--BIOTRONIK, the pioneer in remote monitoring technologies for patients with cardiac devices, announced today the launch of the landmark IMPACT Study (The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients with Implanted ICD and CRT-D devices). The first patient was enrolled at the Thoracic & Cardiovascular Institute in Lansing, MI, USA, which marks the start of this large international, prospective, randomized trial. IMPACT will investigate whether the risk of stroke can be reduced in patients with cardiac devices and asymptomatic atrial fibrillation (AF) by early detection of these arrhythmias utilizing BIOTRONIK´s Home Monitoring technologies and a predefined anticoagulation plan.
